Search 

• EpimAb Biotherapeutics is a biopharmaceutical R&D company based in Shanghai creating a pipeline of novel biologics focused around oncology and other disease areas of high value to patients using its a proprietary, and unique technology called FIT-Ig (Fabs-In-Tandem Immunoglobulin). Company’s pioneer product EMB-01 is a bispecific antibody based on FIT-Ig platform targeting EGFR as well as c-MET, currently is in being investigated for treatment of solid tumors in global Phase I/II clinical trial. EpimAb aims to commercialize its FIT-Ig technology as broadly as possible and maximize the number of programs based on the platform. Further information please visit www.epimab.com
• 岸迈生物科技有限公司是一家总部位于上海的生物制药研发公司。公司基于自主研发的FIT-Ig®双特异性抗体平台技术,聚焦于肿瘤IO领域的创新药品开发。公司的先锋产品EMB-01是一种基于FIT-Ig®平台的双特异性抗体,针对EGFR和c-MET靶点,目前正在进行针对实体瘤的全球I/II期临床试验。岸迈生物的目标是尽可能广泛地将其FIT-Ig®技术商业化,并最大限度地拓展基于该平台的新药开发。更多信息,请访问公司官网www.epimab.com。

FEBICO's current major development of new drug focuses on the treatment of global emerging infectious diseases and hepatitis-related diseases.

1.  Influenza

FEBICO’s Apomivir obtained the approval of US (IND120123) and Taiwan INDs application in 2013 and 2014, respectively. In previous experiments, FB-1603, the active pharmaceutical ingredient of Apomivir, was found to inhibit a variety of viruses in cellular experiments, including influenza A/H1N1, A/H3N2, influenza B, novel influenza viruses (2009), and influenza viruses resistant to tamiflu. Animal experiments have shown oral administration of FB-1603 can effectively reduce the mortality rate of mice caused by influenza A. Apomivir® is designed as oral capsule and given to patients infected with influenza within 48 hours of confirmed infection. The primary outcome measures the time reaching afebrile compared to the control group.

2. COVID-19 (SARs-CoV-2)

The new coronavirus hit the world in 2020, causing tens of millions infections and millions of deaths. In addition to the typical clinical pathology includes respiratory symptoms, severe patients will progress to severe pneumonia, acute respiratory distress syndrome (ARDS) or multiple organ failure, shock or even death. Therefore, the threat is quite big.FB-1603 has been proven in cellular and animal experiments to effectively reduce inflammation and accelerate the healing of scarred tissues. It has also been found in cellular experiments to inhibit pulmonary fibrosis. Because FB-1603 is the active pharmaceutical ingredient of Apomivir. Previous IND 120123 documents and new cellular data against COVID-19 were used to file a pre-IND (151566).

3. Treat liver damage

Current available treatments for liver cancer include surgical resection, liver transplantation, local destruction therapy, transarterial chemoembolization (TACE), chemotherapy and targeted therapy. However, according to clinical literature statistics, about 10% of patients treated with surgical resection or TACE will have postoperative complications such as deterioration of liver function (increased AST/ALT), jaundice, liver failure, and leads to 5% mortality rate. However, there are no effective preventive measures or therapeutic drugs to reduce the incidence of postoperative liver injury. In early phase of clinical trials, it has been observed that FB-1603 help the improvement of patients' liver function after hepatectomy or chemoembolization therapy.

4. Treat Herpes Virus

Herpes virus is a common infectious virus. Depending on the type of virus, it can cause redness and swelling of the skin on the lips or external genitals, resulting in blisters and ulcers, causing stinging and discomfort. Once infected with the herpes virus, the virus will be permanently latent in the human ganglion, and will repeatedly attack when the immune system is weakened. FB1706 has been proven in cellular study to effectively inhibit herpes type 1 and type 2 viruses with a very low dose, and some data show that topical application can shorten the course of the individual’s disease and accelerate the recovery time. The animal module for the herpes virus is currently under establishment. We expect to complete the animal studies before June 2021 and complete documentation of toxicology study and CMC (Chemistry, manufacturing, and control) report.

5. Liver fibrosis treatment

In the past, liver disease was considered a national disease in Asian community. So far, about 10,000 people in Taiwan are diagnosed with liver cancer and 7,700 people die from liver cancer every year. It still ranks as third in cancer incidence and second in mortality. Therefore, chronic liver disease cannot be underestimated. A familiar trilogy is liver inflammation, cirrhosis, and finally liver cancer.

The major cause is that when liver cells are damaged for a long time, liver tissue is formed into fibrosis, leads to hardening of liver, i.e. cirrhosis. Therefore, the key to treatment is to slow down the formation of fibrosis. Currently there is no approved drug to treat liver fibrosis in the world. FB-1807 has been observed in early phase of clinical trials to effectively reduce the liver fibrosis index of liver cancer patients. Preclinical study includes identification of active ingredient and animal studies are currently underway.

 6. Cure Hepatitis B

Chronic hepatitis B virus (HBV) infection is still an important issue of global health, causing nearly one million people die every year from major complications of liver cirrhosis and liver cancer. In recent years, the natural history of HBV and the replication mechanism have been clearly studied. Therefore, it is very important to know how to completely eliminate the virus to prevent viral infection. Although many different drugs have been developed to treat HBV, the long-term use of existing drugs is a heavy burden but still cannot achieve a complete cure. Therefore, a new generation of anti-viral medication is still needed.

FB-1808 has been observed in early clinical trials with significant anti-virus effects. We have confirmed the active ingredient and mechanism study is still ongoing.

Leading healthcare company in china

GEMSEKI facilitates partnering and licensing activities by using web platform and actively reaching out to potential licensees effectively.
GEMSEKI launched in Oct 2017 as a subsidiary of SNBL a public Japanese company (Tokyo Stock Exchange 2395:JP)
We are looking for assets for in-licensing opportunities of our clients.
Also we have several Japanese and non-Japanese assets in oncology, infection, RA/OA , pain and rheumatoid arthritis available for out-licensing.

Global Clinical Trials (GCT) is a premium contract-research organization (CRO) that offers support for the clinical Phase I-IV studies as well as post-marketing activities to Big Pharma, small and medium-sized biotech enterprises, groups and funds, as well as large universities and institutions. Headquartered in Princeton, USA, GCT offers both local and global support through 10 own operational offices in Bulgaria, Czech Republic, Georgia, Hungary, India, Kazakhstan, Latvia, Lithuania, Estonia, Moldova, Poland, Romania, Russia, Slovakia, Ukraine.
GCT team, that now consists of over 100 full-time clinical research professionals, gives individualized attention to each project and provides full range of services following the latest GCP, EMA and FDA guidelines at every stage of product development path. Our monitors and project managers are all certified clinicians experienced in GCP clinical research. Our experience, competent staff, close contact with the KOLs and the immense enrollment potential of the covered region ensure fast study start-up and compliance with the set timelines.
GCT owns 400 sq.m. (4300 ft2) Drug Storage and Distribution facility in St. Petersburg, Russia. It is fully equipped, disaster protected and has multiple modes of storage (ambient, climate controlled, refrigerated, frozen). High standards of work and client satisfaction are proved by the fact that more than 80% of the business come from repeat clients.
Since 2006 GCT is also an Exclusive Partner of “The White Nights” International ophthalmology congress in Russia.

HEC Pharm is the pharmaceutical subsidiaries of HEC Group. There has been a public company listed in Hong Kong in HEC Pharm, and another company will be listed in Shanghai next year.

HEC Pharm focuses on the development and commercialization of pharmaceuticals for the therapeutics of anti-infectious diseases, metabolism disorders and oncology. We are hunting for the opportunities of co-development and in-license of the candidates with the potential therapeutics in previous fields.

A public pharmaceutical company

When your clinical trial has to Overachieve in Central and Eastern Europe, HungaroTrial is here to help. Providing services for Phase 1 through Phase 4 clinical trials in Hungary, Czech Republic, Slovakia, Romania, Serbia, Croatia, Bulgaria, Bosnia, Poland, Ukraine, Belgium and Russia, HungaroTrial is the CEE region’s leading independent CRO.

To Overachieve, your clinical trial needs the best minds from beginning to end. That’s why Hungarotrial’s full-time staff includes 12 MDs of various specialties,more than any other independent CRO in the region. And you can be assured that our experienced team has built strong relationships with the most respected Key Opinion Leaders in CEE.

Our staff’s broad medical experience means that your clinical study benefits from diverse skills and synergistic teamwork. Over the past 18 years, HungaroTrial has become well known not just for this broad expertise, but also for our deep experience in Oncology, Rheumatology, Cardiovascular diseases, PAO, CNS and some other focus therapeutic areas.

Founded in 2017, it has been the mission of Nanjing IASO Biotherapeutics (IASO BIO) to become a leading biopharmaceutical company focused on the discovery, development and commercialization of cell therapies in the field of oncology.

IASO BIO stands out through innovation, a world class facility, and an internationally renowned clinical research team that has treated more than 400 patients. Curing many who continually failed through multiple-lines of therapy, by means of detailed and thorough pathological analysis and follow up.

IASO BIO is dedicated to curing cancer using engineered autologous/allogenic T cell therapies designed to enhance the immune system's ability to recognize and eradicate cancer cells. Safety is dramatically enhanced via a proprietary procedure, minimizing the severity of CRS. Currently, IASO BIO is developing over 10 high-potential pharmaceutical products, targeting hematological tumors, solid tumors and virus associated tumors at different clinic stages.